European Heart Journal, Supplement
European Heart Journal, Supplement is a journal indexed in SJR in Cardiology and Cardiovascular Medicine with an H index of 43. It has an SJR impact factor of 0,68 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,68.
Metrics
Scimago and CountryOfPapers database fields
SJR Impact
0,68
H-index
43
Docs (year)
74
Docs 3y
377
Total refs
1876
Cites 3y
793
Citable 3y
370
Cites/Doc 2y
2.38
Ref/Doc
25.35
Immediate OA
—
Embargoed OA
NPD
Non OA / Submission
—
Name good journals. Call out predatory ones.
Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.
Researcher reviews
Best articles by citations
Arrhythmia substrate and management in hypertrophic cardiomyopathy: from molecules to implantable card ioverter-defibrillators
View moreVal-HeFT: changing the heart failure horizon
View moreDiabetology for cardiologists
View moreDiabetes and the heart: compromised myocardial function ? a common challenge
View moreCoronary revascularization: knife or catheter?
View moreCoronary heart disease risk in Japan ? an East/West divide?
View moreContribution of bradykinin to the cardioprotective effects of ACE inhibitors
View moreContrast echocardiography and medical economics: looking into the crystal ball
View moreClinical utility of contrast echocardiography in the management of patients with acute myocardial infarction
View moreCan n-3 fatty acids provide myocardial protection by decreasing infarct size and inhibiting atherothrombosis?
View moreBringing VALUE to LIFE
View moreBiochemistry and physiology of eicosanoid precursors in cell membranes
View moreAT1 receptors in atherosclerosis: biological effects including growth, angiogenesis, and apoptosis
View moreA disturbed glucose metabolic state (dysglycaemia) is a key risk factor for cardiovascular events
View moreAre diets high in omega-6 polyunsaturated fatty acids unhealthy?
View moreAntithrombin therapy, antiplatelet therapy and percutaneous coronary intervention: rationale and design of the SYNERGY trial
View moreAntitachycardia pacing therapy to treat spontaneous atrial tachyarrhythmias: the 7250 dual defibrillator Italian Registry
View moreAntitachycardia pacing therapies to terminate atrial tachyarrhythmias: the AT500 Italian Registry
View moreAntiplatelet strategies*1
View moreAntioxidants and atherosclerosis
View moreAngiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril
View moreAngiotensin receptor blockers and the cardiovascular continuum: what future is indicated by recent successes?
View moreAngiotensin II overproduction: enemy of the vessel wall
View moreAlpha-linolenic acid in the prevention and treatment of coronary heart disease
View more